PET aSyn vendor matrix (AC Immune / MODAG / University of Zurich / QST / Shenzhen / Merck / Mass Generic at Brigham) — Lead compound, Derivative, Structure, patient, Timeline, detects, in vitro Saturation binding affinity, IF, ARG, Preclinical Tox start

PET aSyn vendor matrix

AC ImmuneMODAGUniversity of ZurichQST (Takeda, QST, Eisai, and Ono)ShenzhenMerckMass Gener at Brigham
Lead compoundACI-3847 / ACI-12589 / ACI-15916SPAL-T-6C05-05 / SPAL-T-95FOSO28MK-7337
Derivative of what?Pbb3 (a tau protein pet tracer)benzothiazole-benzofuran-phenol derivative
Structure(Smith, 2023 #2765), Not found in cortellsNYBB 2023/0840 wo etc
TimelineFY2020 4Q FH DLB/PD w/ or w/o A6 and tauNot prioritized2nd FH candidate (One 2021 #2305)(Xiang, 2023 #2397) A FH to begin in 2023preparation tracer for use; In to humans 2023, In trials
detectsMorphomer platform 일정 thioflavin (oligo) PFF (recombinant 일정) oligomers with 2-6 nMbind fibril forms of α5 but not soluble monomeric form because the series comes from β-sheet binder candidate 잡고 PFF (오리고머 fibril/Monomer ratio etc); (screening) aSyn PFF; candidate aSyn PFF tracer (PFF/Monomer ratio etc)
Current homeostates / in vitro (source?) / Saturation binding affinitySaturation binding affinity, with values of 4 nM and 22 nM brain homogenates from people with PD and MSA respectively.

Kd: 18-35nM (PM)
5-1) Homologous binding with brain homo, fig30

DLB brain homogenates: CC50-1.58 IC50-10.86 AAA before 3-1
DLB brain homogenates of MSA-P putamen: 1 (affinity-binding) homologues of MSA-P 2.4 BnM ii) (selectivity) the blind binding was inhibited by neither cilengitide a MAO-A inhibitor (red symbols), nor selegiline a MAO-B inhibitor (green symbols) at varying concentrations.
1) IF in patient brain sections (Selectivity α-syn preferred (αSyn vs tau) ie [αsyn] AGE α-syn aging fluid 1) IF in vivo 2-photon microscopy in PFF injected mouse brain ; aSyn 약 30nM 일정 인 일정 propose 비교 의용 / IF compared to NHP-aSyn fix(Xiang, 2023 #2397) IC: 2-6-50nM patient (PD vs HC vs AS); HCl only 1.2x [no quantification](Matsuoka, 2022 #2127) figs MSA-P patient brain section a Kd PFF (no quantification); These sections were then used for fluorescence staining with non-radio-labelled SPAL-T-06 (30µM) and pcl129 revealing ABUNDANT pcl in the putamen of the MSA-P case (no quantification)1) IF in patient brain sections (familial PD : DLB ; PDD MSA: distribution in these brain sections matched IHC of α-asyn; suggesting that the tracer binds its target a Kd of 17 nM cortex of PD 30 nM cell MSA)
IFThis tracer bound to brainstem and midbrain sections in people with MSA AND DLB; as well as cerebellar white matter in people with MSA; [No labeling] (Matsuoka, 2022 #2127) figs MSA-P patient brain section was Kd PFF (no quantification); Cell sections then used for fluorescence staining with non-radiolabeled SPAL-T-06 (30µM) and pcl129; revealing ABUNDANT pcl in the putamen of the MSA-P case (no quantification)
ARGvs HC; Cold (-); Hot (HCl only 1.2x); Cold; (A30P mice Kd 0.917nm Bmax 30nM); FIG1 IF AAV α-asyn mice patient (MSA DLB) FIG3 IF WT mice 5xFAD Tau P3015 AAV-α-asyn AS3T mice α-injected FOSO28 (2 quantification); mouse striatum → PET scan of (PFF mice and PFF NHP) (marmosette); (Ono 2021 #2305) C11-MODAG-001 in the entered brain & midbrain sections compared to a... fight ASYN PFF in 'aged ASYP α-syn neuron-specific binding signal that overlaps with α-syn pathology in the medium and brain stem of MSA mouse SUVR signal
ARG / desirable PK characteristics in NHP

Preclinical Tox (start)

  • [non-GLP] Two studies in rat

(plus a partial line or tangle accumulation.)